Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2026 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

rezolute inc - RZLT

RZLT

Close Chg Chg %
2.51 -0.03 -1.20%

Closed Market

2.48

-0.03 (1.20%)

Volume: 3.69M

Last Updated:

Jan 13, 2026, 4:00 PM EDT

Trade Now

Company Overview: rezolute inc - RZLT

RZLT Key Data

Open

$2.50

 Day Range

2.36 - 2.58

52 Week Range

1.07 - 11.46

 Market Cap

$232.75M

Shares Outstanding

92.73M

 Public Float

74.99M

Beta

0.40

 Rev. Per Employee

N/A

P/E Ratio

N/A

 EPS

-$0.93

Yield

0.00%

 Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

8.09M

  

RZLT Performance

1 Week
 
 -5.70%
 
1 Month
 
 37.78%
 
3 Months
 
 -71.46%
 
1 Year
 
 -49.08%
 
5 Years
 
 -81.70%
 

RZLT Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 10
Full Ratings ➔

About rezolute inc - RZLT

Rezolute, Inc. operates as a biopharmaceutical company, which engages in the development of drug therapies for patients with metabolic and orphan diseases. The firm's antibody therapy, ersodetug, is designed to treat all forms of hyperinsulinism. The company was founded by Nevan Charles Elam, Ho Young Huh, and Sankaram Mantripragada in March 2010 and is headquartered in Redwood City, CA.

RZLT At a Glance

Rezolute, Inc.
275 Shoreline Drive
Redwood City, California 94065
Phone 1-650-206-4507 Revenue 0.00
Industry Pharmaceuticals: Major Net Income -74,412,000.00
Sector Health Technology Employees 71
Fiscal Year-end 06 / 2026
View SEC Filings

RZLT Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio N/A
Price to Book Ratio 2.393
Price to Cash Flow Ratio N/A
Enterprise Value to EBITDA -2.163
Enterprise Value to Sales N/A
Total Debt to Enterprise Value 0.009

RZLT Efficiency

Revenue/Employee N/A
Income Per Employee -1,048,056.338
Receivables Turnover N/A
Total Asset Turnover N/A

RZLT Liquidity

Current Ratio 14.367
Quick Ratio 14.367
Cash Ratio 14.092

RZLT Profitability

Gross Margin N/A
Operating Margin N/A
Pretax Margin N/A
Net Margin N/A
Return on Assets -48.284
Return on Equity -52.564
Return on Total Capital -45.445
Return on Invested Capital -52.078

RZLT Capital Structure

Total Debt to Total Equity 0.996
Total Debt to Total Capital 0.986
Total Debt to Total Assets 0.92
Long-Term Debt to Equity 0.606
Long-Term Debt to Total Capital 0.60
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Rezolute Inc - RZLT

Collapse All in section
All values USD millions. 2022 2023 2024 2025 5-year trend
Sales/Revenue
- - - -
-
Sales Growth
- - - -
-
Cost of Goods Sold (COGS) incl D&A
256.00K 382.00K 36.00K 31.00K
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
256.00K 382.00K 36.00K 31.00K
Depreciation
256.00K 382.00K 36.00K 31.00K
Amortization of Intangibles
- - - -
-
COGS Growth
+1,869.23% +49.22% -90.58% -13.89%
Gross Income
(256.00K) (382.00K) (36.00K) (31.00K)
Gross Income Growth
-1,869.23% -49.22% +90.58% +13.89%
Gross Profit Margin
- - - -
-
2022 2023 2024 2025 5-year trend
SG&A Expense
41.59M 55.61M 70.39M 79.86M
Research & Development
32.49M 43.81M 55.74M 61.53M
Other SG&A
9.10M 11.79M 14.64M 18.34M
SGA Growth
+81.75% +33.71% +26.58% +13.46%
Other Operating Expense
- - - -
-
Unusual Expense
- (2.51M) 5.00K 2.91M
EBIT after Unusual Expense
(39.33M) (56.00M) (73.33M) (79.89M)
Non Operating Income/Expense
80.00K 4.21M 4.87M 5.48M
Non-Operating Interest Income
80.00K 4.21M 4.87M 5.48M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
- - - 1.81M
-
Interest Expense Growth
- - +381.87% -100.00%
-
Gross Interest Expense
- - - 1.81M
-
Interest Capitalized
- - - -
-
Pretax Income
(41.06M) (51.79M) (68.46M) (74.41M)
Pretax Income Growth
-96.44% -26.13% -32.19% -8.70%
Pretax Margin
- - - -
-
Income Tax
- - - -
-
Income Tax - Current - Domestic
- - - -
-
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
- - - -
-
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(41.06M) (51.79M) (68.46M) (74.41M)
Minority Interest Expense
- - - -
-
Net Income
(41.06M) (51.79M) (68.46M) (74.41M)
Net Income Growth
-96.44% -26.13% -32.19% -8.70%
Net Margin Growth
- - - -
-
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(41.06M) (51.79M) (68.46M) (74.41M)
Preferred Dividends
- - - -
-
Net Income Available to Common
(41.06M) (51.79M) (68.46M) (74.41M)
EPS (Basic)
-2.2564 -1.0117 -1.3302 -0.9791
EPS (Basic) Growth
+17.19% +55.16% -31.48% +26.39%
Basic Shares Outstanding
18.20M 51.19M 51.47M 76.00M
EPS (Diluted)
-2.3159 -1.0117 -1.3302 -0.9791
EPS (Diluted) Growth
+15.01% +56.32% -31.48% +26.39%
Diluted Shares Outstanding
19.49M 51.19M 51.47M 76.00M
EBITDA
(41.59M) (55.61M) (70.39M) (79.86M)
EBITDA Growth
-81.75% -33.71% -26.58% -13.46%
EBITDA Margin
- - - -
-

Snapshot

Average Recommendation OVERWEIGHT Average Target Price 4.125
Number of Ratings 10 Current Quarters Estimate -0.169
FY Report Date 03 / 2026 Current Year's Estimate -0.70
Last Quarter’s Earnings -0.195 Median PE on CY Estimate N/A
Year Ago Earnings -0.98 Next Fiscal Year Estimate -0.693
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 10 10 10 10
Mean Estimate -0.17 -0.17 -0.70 -0.69
High Estimates -0.09 -0.07 -0.49 -0.46
Low Estimate -0.22 -0.25 -0.83 -0.98
Coefficient of Variance -27.59 -37.08 -18.23 -26.96

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 6 6 10
OVERWEIGHT 0 0 0
HOLD 4 4 0
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Overweight Overweight Buy

Insider Actions for Rezolute Inc - RZLT

Date Name Shares Transaction Value
Jun 25, 2025 Daron G. Evans CFO 268,900 Open market or private purchase of non-derivative security Non-derivative transaction at $4.05 per share 1,089,045.00
Jun 24, 2025 Handok, Inc. Director 8,423,386 Open market or private purchase of non-derivative security Non-derivative transaction at $3.25 per share 27,376,004.50
Apr 2, 2025 Wladimir Hogenhuis Director 84,025 Open market or private purchase of non-derivative security Non-derivative transaction at $2.92 per share 245,353.00
Apr 1, 2025 Nevan Charles Elam CEO; Director 224,119 Open market or private purchase of non-derivative security Non-derivative transaction at $2.84 per share 636,497.96
Feb 21, 2025 Wladimir Hogenhuis Director 15,000 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 21, 2025 Wladimir Hogenhuis Director 77,267 Open market or private purchase of non-derivative security Non-derivative transaction at $4.7 per share 363,154.90
Feb 20, 2025 Gilbert M. Labrucherie Director 15,000 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 20, 2025 Nerissa C. Kreher Director 15,000 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 20, 2025 Nerissa C. Kreher Director 25,500 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 20, 2025 Brain Roberts Chief Medical Officer 45,000 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 20, 2025 Brain Roberts Chief Medical Officer 131,352 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 20, 2025 Philippe Fauchet Director 15,000 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 20, 2025 Philippe Fauchet Director 25,500 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 20, 2025 Gilbert M. Labrucherie Director 25,500 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 20, 2025 Young-Jin Kim Director 15,000 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 20, 2025 Young-Jin Kim Director 140,950 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 20, 2025 Handok, Inc. Director 7,192,617 Open market or private purchase of non-derivative security Non-derivative transaction at $4 per share 28,770,468.00
Feb 20, 2025 Daron G. Evans CFO 45,000 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Feb 20, 2025 Nevan Charles Elam CEO; Director 120,000 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00

Rezolute Inc in the News